Mode
Text Size
Log in / Sign up
N/A Completed N=4 Treatment

Safety Study of Cell Therapy to Treat Chronic Obstructive Pulmonary Disease

Source: ClinicalTrials.gov NCT01110252 ↗
Enrolled (actual)
4
Serious AEs
0.0%
Results posted
Mar 2012
Primary outcomePrimary: Forced Vital Capacity (FVC) — 1.5; 2.1 liters

Summary

The purpose of this study is to determine whether the cell therapy with bone marrow mononuclear cells is safe in the treatment of chronic obstructive pulmonary disease, specifically the pulmonary emphysema.

Outcome Measures

OutcomeResultp-value
PRIMARY
Forced Vital Capacity (FVC)
1.5; 2.1 —
PRIMARY
Forced Expiratory Volume (FEV1)
0.7; 0.8 —
PRIMARY
Vital Capacity - VC
1.8; 1.4 —
SECONDARY
Arterial Blood Gases Test - Pa O2
69; 57 —
SECONDARY
Arterial Blood Gases Test - Pa CO2
48.75; 89.25 —

Eligibility Criteria

Inclusion Criteria

  • diagnosis of severe chronic obstructive pulmonary disease
  • ineffective clinical treatment
  • limited life expectancy
  • limitations in daily physical activity
  • possibility of pulmonary rehabilitation physiotherapy
  • acceptable nutritional status
  • acceptable cardiac function
  • at least six months smoking cessation
  • family support
  • modified medical research council dyspnea scale stage > 3

Exclusion Criteria

  • pulmonary or extra-pulmonary infection
  • severe coronary disease and/or ventricular dysfunction
  • significant kidney or liver disease
  • immunosuppressive disease
  • active smoker
  • cancer
  • psychosocial problems
  • established medical protocol
  • family rejection
  • pregnancy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01110252). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search